Publications

Purdue’s Medical Information department is committed to providing balanced and accurate scientific and clinical information on Purdue products to help you make informed healthcare decisions. As a company founded by physicians, Purdue values the opportunity to communicate with healthcare professionals about the clinical information related to our medications.


Publications

Compendia Review

Purdue’s Medical Information department proactively and regularly reviews various drug information compendia to ensure Purdue product monographs are accurate, complete, and up-to-date as these resources are often utilized by healthcare professionals and consumers to help inform treatment decisions.

Collaborative Compendia Review Project

A collaborative initiative, led by Purdue Pharma, involving medical information specialists from 11 pharmaceutical companies proactively reviewed 270 drug summaries for 54 prescription drug products within 5 commonly used online drug information compendia for misinformation. An alarming number of errors were identified in these top online drug information compendia. This study highlights need for healthcare professionals and consumers to utilize more than one drug information resource, one of which may include a pharmaceutical company’s medical information department, to obtain accurate and balanced product-specific information to help support treatment decisions.1

Complete study results were published online in the Annals of Pharmacotherapy on February 25, 2016 and are available here. Purdue’s press release describing the study and results is also available here.

Purdue Compendia Review

Between 2011 and 2013, pharmacists from the Medical Information department systematically reviewed drug summaries for Purdue’s opioid analgesic products within 7 leading online drug information compendia for misinformation. Content corrections for errors were then submitted to compendia editors and retrospectively categorized and classified. At least two months following submission, the same drug summaries were then reexamined to assess the degree of error resolution.2

A total of 859 errors were identified, with the greatest percentage in Safety and Patient Education categories. Across the 7 compendia, the complete or partial resolution of errors was 34%; therefore, nearly two-thirds of the identified errors remain. Given the misinformation identified in this study, healthcare professionals and consumers seeking reliable, on-label drug product information should consult multiple sources, including a product’s Full Prescribing Information as well as manufacturers’ medical information departments.2

Complete study results were published online in the Journal of Opioid Management in August 2016 and are
available here. Purdue’s press release describing the study and results is also available here.

Reference

  1. Randhawa AS, et al. A collaborative assessment among 11 pharmaceutical companies of misinformation in commonly used online drug information compendia. Ann Pharmacother. 2016;50(5):352-359. doi: 10.1177/1060028016635196.  http://aop.sagepub.com/content/50/5/352.long
  2. Talwar SR, Randhawa AS, Dankiewicz EH, et al. Caveat emptor: Erroneous safety information about opioids in online drug-information compendia. J Opioid Manag. 2016 Jul/Aug. http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/330/pdf

 

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.